Manuscript accepted on :
Published online on: --
Bijan Rezakhaniha¹* and Soheila Siroosbakhat2
1Department of Urology, Imam Reza Hospital, Tehran, Iran. 2Medical College, AJA University of Medical Sciences,,Tehran, Iran.
ABSTRACT: Premature ejaculation is the most common type of sexual dysfunction in men younger than 40 years. The optimal medical treatment for premature ejaculation has not been established in previous studies, but single dosing prior to sexual relations can work for some males, while in others, achieving a blood level through daily use of the medication may be necessary, as in the treatment of clinical depression. Obviously, if single dosing is successful, therapy is simpler and is associated with fewer adverse effects. Therefore, this may be the preferred initial therapy. Hence in this study, two therapeutic protocols of citalopram including as needed and twice a day were compared. This study was an un-blind randomized clinical trial. The patients aged older than 18 years with premature ejaculation were evaluated by urologist and after the disease was established and the questionnaire was fulfilled they were enrolled into the study. The patients were randomly assigned to receive either twice a day 20 mg citalopram or 20 mg four hours before coitus. The mean ejaculation time in two groups of PRN and BD was significantly differed in fourth week (P < 0.05) with 286.9±252.6 and 269.51±350.21 seconds, respectively, but apposite of BD group (485.±519.93 seconds), the patients in PRN group (288.53±267.27 seconds) showed no significant difference (P > 0.05), and however the baseline and fourth week measurement were alike between two groups; but in eighth week after treatment there was a significant difference between two groups (P < 0.05). Totally, it may be concluded that citalopram with every dose is effective in the treatment of premature ejaculation. However the BD regimen is more effective.
KEYWORDS: Premature ejaculation; Citalopram; Impotency; Clinical trial; Sexual dysfunctionDownload this article as:
This work is licensed under a Creative Commons Attribution 4.0 International License.